A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia

Blood

Volumn 122, Issue 7, 2013, Pages 1222-1232

  Yang, Guang ^a,b   Zhou, Yangsheng ^a,b   Liu, Xia ^a,b   Xu, Lian ^a   Cao, Yang ^a,b   Manning, Robert J ^a   Patterson, Christopher J ^a   Buhrlage, Sara J ^a,b   Gray, Nathanael ^a,b   Tai, Yu Tzu ^a,b   Anderson, Kenneth C ^a,b   Hunter, Zachary R ^a,b   Treon, Steven P ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRUTON TYROSINE KINASE; I KAPPA B KINASE ALPHA; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHOPROTEIN; AGAMMAGLOBULINAEMIA TYROSINE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; IRAK1 PROTEIN, HUMAN; LUCIFERASE; MYD88 PROTEIN, HUMAN; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CELL KILLING; CELL SURVIVAL; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOMATIC MUTATION; WALDENSTROEM MACROGLOBULINEMIA; CASE CONTROL STUDY; CELL CULTURE; CELL PROLIFERATION; DRUG ANTAGONISM; FLOW CYTOMETRY; GENETICS; LENTIVIRINAE; LYMPHOCYTE; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELLS, CULTURED; FLOW CYTOMETRY; HUMANS; IMMUNOPRECIPITATION; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; LENTIVIRUS; LUCIFERASES; LYMPHOCYTES; MUTATION; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; WALDENSTROM MACROGLOBULINEMIA;

EID: 84883876958     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-475111     Document Type: Article

References (32)

1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003;30(2):110-115.
2. Swerdlow S, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: IARC Press; 2008: 194-195
3. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med. 2012;367(9): 826-833.
4. Gachard N, Parrens M, Soubeyran I, et al. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/ lymphoplasmacytic lymphomas. Leukemia. 2013; 27(1):183-189.
5. Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013; 121(11):2051-2058.
6. Varettoni M, Arcaini L, Zibellini S, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms. Blood. 2013;121(13): 2522-2528.
7. Jiménez C, Sebastián E, Del Carmen Chillón M, et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia [published online ahead of print February 28, 2013]. Leukemia.
8. Willenbacher W, Willenbacher E, Brunner A, Manzl C. Improved accuracy of discrimination between IgM multiple myeloma and Waldenström macroglobulinaemia by testing for MYD88 L265P mutations. Br J Haematol. 2013; 161(6):902-904.
9. Landgren O, Staudt L. MYD88 L265P somatic mutation in IgM MGUS [letter]. N Engl J Med. 2012;367(23):2255-2256.
10. Treon SP, Xu L, Hunter ZR. The authors reply: MYD88 L265P somatic mutation in IgM MGUS [letter]. N Engl J Med. 2012;367(23): 2256-2257.
11. Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332): 115-119.
12. Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43(9): 830-837.
13. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011; 475(7354):101-105.
14. Montesinos-Rongen M, Godlewska E, Brunn A, Wiestler OD, Siebert R, Deckert M. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathol. 2011;122(6): 791-792.
15. Watters TM, Kenny EF, O’Neill LA. Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins. Immunol Cell Biol. 2007;85(6): 411-419.
16. Loiarro M, Gallo G, Fantò N, et al. Identification of critical residues of the MyD88 death domain involved in the recruitment of downstream kinases. J Biol Chem. 2009;284(41): 28093-28103.
17. Lin SC, Lo YC, Wu H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature. 2010;465(7300): 885-890.
18. Kawagoe T, Sato S, Matsushita K, et al. Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nat Immunol. 2008;9(6):684-691.
19. Cohen L, Henzel WJ, Baeuerle PA. IKAP is a scaffold protein of the IkappaB kinase complex. Nature. 1998;395(6699):292-296.
20. Loiarro M, Sette C, Gallo G, et al. Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependent activation of NF-kappaB. J Biol Chem. 2005; 280(16):15809-15814.
21. Powers JP, Li S, Jaen JC, et al. Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4. Bioorg Med Chem Lett. 2006;16(11):2842-2845.
22. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621-681.
23. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440-446.
24. Windheim M, Stafford M, Peggie M, Cohen P. Interleukin-1 (IL-1) induces the Lys63-linked polyubiquitination of IL-1 receptor-associated kinase 1 to facilitate NEMO binding and the activation of IkappaBalpha kinase. Mol Cell Biol. 2008;28(5):1783-1791.
25. Tai YT, Chang BY, Kong SY, et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. 2012;120(9):1877-1887.
26. Liu X, Zhan Z, Li D, et al. Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat Immunol. 2011;12(5): 416-424.
27. Ahmad-Nejad P, Häcker H, Rutz M, Bauer S, Vabulas RM, Wagner H. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol. 2002;32(7): 1958-1968.
28. Leleu X, Eeckhoute J, Jia X, et al. Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood. 2008;111(10): 5068-5077.
29. Shinners NP, Carlesso G, Castro I, et al. Bruton’s tyrosine kinase mediates NF-kappa B activation and B cell survival by B cell-activating factor receptor of the TNF-R family [published correction appears in J Immunol. 2007;179(9):6369]. J Immunol. 2007;179(6):3872-3880.
30. Bajpai UD, Zhang K, Teutsch M, Sen R, Wortis HH. Bruton’s tyrosine kinase links the B cell receptor to nuclear factor kappaB activation. J Exp Med. 2000;191(10):1735-1744.
31. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/ refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88-94.
32. Treon SP, Tripsas C, Palomba L, et al. A prospective, multicenter, phase II study of the Bruton’s tyrosine kinase inhibitor ibrutinib in patients with Waldenstrom’s macroglobulinemia [abstract]. Hematol Oncol 2013;31:119 (Abstract 67).